About a year ago, Tenvie President and Chief Scientific Officer Tony Estrada approached Denali CEO Ryan Watts and others in the Denali team with a proposal to spin out the small-molecule drugs with ...

The biotech, called Tenvie Therapeutics, launched Wednesday with $200 million from ARCH Venture Partners — one of Denali’s early investors — as well as F-Prime Capital, Mubadala Capital ...

Tenvie Therapeutics has unveiled with $200 million and the goal of transforming the neurological treatment landscape, nabbing several programs—and an executive—from Denali Therapeutics.

Advancing a deep pipeline of therapeutics focused on treating neurological, cardiometabolic, and ophthalmic diseases Led by expert R&D leadership team with proven ability to develop therapies for CNS ...

It's JPM 2025 and here at Fierce Biotech we’re bringing you all the latest updates live from the life sciences event of the ...

Jan. 08, 2025 (GLOBE NEWSWIRE) -- Tenvie Therapeutics launched today with ... including programs acquired from Denali Therapeutics Inc., with a proven team of research and development leaders.

Tenvie Therapeutics has launched with $200 million and a clutch of assets from Denali Therapeutics to go after neurological diseases with small molecules. Backed by ARCH Venture Partners, F-Prime ...